12 results about "Fluvastatin" patented technology

The present invention provides the use of a reagent for detecting a target compound combination in the preparation of a detection agent, and the detection agent is used for screening and identifying whether a subject under test has taken drugs for treating vertigo, syncope or stroke, and assisting in determining whether the subject suffers from related diseases. Among them, the target compound combination includes one, several or all of lidocaine, cinepazide maleate, ticlopidine, penbutolol, fendiline, cinnarizine, clopidogrel, midodrine, dipyridamole, argatroban, rosuvastatin, atorvastatin, fluvastatin, and pitavastatin. The plasma sample pretreatment method of the present invention is simple, the detection and analysis time is short, the sensitivity of the method is high, and the types and quantities of detections are many; the method is divided into a primary screening method and a review method, which can improve the accuracy of the detection results and avoid false negative and false positive results.

A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs.

The present invention discloses a synthesis process for a key intermediate of fluvastatin. The process comprises a simple condensation reaction similar to an aldol condensation reaction, followed by reduction of a nitro derivative and a double bond reaction to obtain an indole ring, and finally, introduction of an isopropyl group, thereby obtaining the key intermediate compound V of fluvastatin. The present invention has the following beneficial effects: the raw materials used in each step of the present invention are readily available and relatively low in price, which can effectively reduce production costs, save production costs, and bring considerable economic benefits; the reagents used in the present invention are less hazardous, generate less waste, and are simple to handle, with less harm, which is beneficial to environmental protection, energy conservation, and emission reduction, conforming to the concept of green chemistry; the reaction route of the present invention is simple to operate, has a high product yield, generates few by-products, has high product purity, good atom economy, and is easy to separate, making it suitable for industrial scale-up production.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

The invention belongs to the technical field of biological medicines, and relates to a compound for enhancing the targeting property of an antitumor drug as well as a preparation method and application of the compound. The invention provides a compound for enhancing the targeting property of an anti-tumor drug. The compound is composed of a carrier, the anti-tumor drug and a targeting drug, the targeted drugs are tinidazole and methimazole; in the compound, the proportion of the targeted drug is not less than 3% based on the carrier dosage; the carrier is albumin; the antitumor drug is fluvastatin. The invention provides an intervention strategy for synchronously targeting lipid raft metabolism and mitochondrial respiration so as to realize effective activation of T cells in a tumor microenvironment. The compound constructed by the invention is based on a dual response targeting mechanism of tinidazole and methimazole to a tumor microenvironment, so that the targeting property of fluvastatin to tumors is improved, and more solutions are provided for the fluvastatin to safely and effectively regulate and control a metabolic pathway of tumor cells.

The present invention is directed to solid, sustained-release, oral dosage form pharmaceutical compositions which contain therapeutic amount of a pharmaceutically acceptable salt of fluvastatin; hydroxypropyl methyl cellulose; and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000 for the reduction of plasma cholesterol levels.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and / or naltrexone.

A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.

This invention relates to the field of biomedical technology. It provides a pharmaceutical composition comprising fluvastatin and tanshinone as active ingredients, and further provides its application in the preparation of formulations for the prevention and / or treatment of radiation-induced lung injury. This invention utilizes the synergistic effect of fluvastatin and tanshinone to intervene in the pathogenesis of radiation-induced lung injury from multiple targets and pathways, significantly improving prevention and treatment efficacy. It can alleviate the inflammatory symptoms of radiation-induced pneumonia and delay the progression of radiation-induced pulmonary fibrosis, with low side effects, high safety, and wide applicability, providing a new drug option and technical solution for the clinical prevention and treatment of radiation-induced lung injury.

The invention discloses a novel application of fluvastatin in treatment of paclitaxel drug-resistant non-small cell lung cancer. It is found for the first time that fluvastatin can significantly inhibit proliferation, migration and invasion of paclitaxel drug-resistant non-small cell lung cancer cells A549 / Tax, can induce A549 / Tax cell apoptosis and can be used for developing drugs for treating paclitaxel drug-resistant non-small cell lung cancer. The invention provides a theoretical basis for research and development of drugs for treating the paclitaxel drug-resistant non-small cell lung cancer, opens up a new application of fluvastatin, provides a brand new method for treating the paclitaxel drug-resistant non-small cell lung cancer, and has a wide application prospect in the technical field of treatment of the paclitaxel drug-resistant non-small cell lung cancer.

The present invention is directed to a solid, sustained-release, oral dosage form pharmaceutical composition which contains a therapeutic amount of fluvastatin,hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from the group consisting of hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000.